Drugs / ALT-836
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01325558 | May 2011 → Aug 2012 | cancer | Altor BioScience | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00879606 | Apr 2009 → Oct 2012 | acute lung injury, acute respiratory distress syndrome, infectious disease with sepsis | Altor BioScience | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALT-836 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01325558 ↗ |
| Action | Inhibit | “anti-TF antibody blockage of TF activity” NCT00879606 ↗ |
| Modality | Monoclonal antibody | “a recombinant human-chimeric monoclonal antibody” NCT01325558 ↗ |
| Route | Intravenous | “via intravenous infusion over 15 minutes” NCT00879606 ↗ |